Literature DB >> 16930497

Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms.

Catherine A Thomas1, Yao-Chi Chuang, Antonella Giannantoni, Michael B Chancellor.   

Abstract

Botulinum neurotoxin (BoNT) has been called the most poisonous poison and a potential bioterrorism weapon, and yet modern medicine has been able to harvest the elegant and specific activity of this toxin to treat a variety of medical conditions. BoNT application recently has been extended to prostate disorders, and this article reviews the literature on the mechanisms of action and clinical efficacy of BoNT treatment in the prostate. BoNT has demonstrated promising preliminary results for male lower urinary tract symptoms, and translational research suggests novel mechanism of action of BoNT in the prostate. It is important to remember that the application of BoNT in the prostate is not approved by the regulatory agencies and caution should be applied until larger randomized clinical studies are completed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16930497     DOI: 10.1007/s11934-996-0005-1

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  28 in total

1.  Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles.

Authors:  H Ishikawa; Y Mitsui; T Yoshitomi; K Mashimo; S Aoki; K Mukuno; K Shimizu
Journal:  Jpn J Ophthalmol       Date:  2000 Mar-Apr       Impact factor: 2.447

2.  Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.

Authors:  M J Welch; J R Purkiss; K A Foster
Journal:  Toxicon       Date:  2000-02       Impact factor: 3.033

Review 3.  Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions.

Authors:  K R Aoki; B Guyer
Journal:  Eur J Neurol       Date:  2001-11       Impact factor: 6.089

4.  Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland.

Authors:  Yao-Chi Chuang; Chao-Cheng Huang; Hong-Yo Kang; Po-Hui Chiang; Fernando Demiguel; Naoki Yoshimura; Michael B Chancellor
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

5.  Treatment of benign prostatic hyperplasia.

Authors:  P C Walsh
Journal:  N Engl J Med       Date:  1996-08-22       Impact factor: 91.245

Review 6.  The pathophysiology of lower urinary tract symptoms in the ageing male population.

Authors:  H Lepor
Journal:  Br J Urol       Date:  1998-03

7.  Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates.

Authors:  Hann-Chorng Kuo
Journal:  Urology       Date:  2005-04       Impact factor: 2.649

Review 8.  The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies.

Authors:  J N Pennefather; W A Lau; F Mitchelson; S Ventura
Journal:  J Auton Pharmacol       Date:  2000-08

9.  Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.

Authors:  Giorgio Maria; Giuseppe Brisinda; Ignazio Massimo Civello; Anna Rita Bentivoglio; Gabriele Sganga; Alberto Albanese
Journal:  Urology       Date:  2003-08       Impact factor: 2.649

10.  Subcutaneous administration of botulinum toxin A reduces formalin-induced pain.

Authors:  Minglei Cui; Sid Khanijou; John Rubino; Kei Roger Aoki
Journal:  Pain       Date:  2004-01       Impact factor: 6.961

View more
  1 in total

Review 1.  Acetylcholine for male LUTS.

Authors:  Steven J Weissbart; Bilal Chughtai; Dean Elterman; Richard Lee; Alexis Te; Steven Kaplan
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.